NAD Recommends Dr. Harold Katz Discontinue Health-Performance Claims for Therabreath Rinse, Lozenges; Company to Appeal

New York, NY – Jan. 8, 2018 – The National Advertising Division has recommended Dr. Harold Katz, LLC, discontinue certain advertising claims for the company’s Therabreath Dry Mouth Treatment products, including claims that the products “relieve” or “fight” dry mouth symptoms. The company said it will appeal NAD’s adverse findings to the National Advertising Review Board.

NAD is an investigative unit of the advertising industry’s system of self-regulation and is administered by the Council of Better Business Bureaus.

The claims at issue were challenged before NAD by GlaxoSmithKline Consumer Healthcare, L.P., the manufacturer of competing Biotene brand oral care products.

At the outset of NAD’s inquiry, the advertiser informed NAD that it would permanently discontinue a number of the challenged claims and modify others and would only make dry mouth related claims for two products: TheraBreath Dry Mouth Oral Rinse and TheraBreath Dry Mouth Lozenges.

Further, the advertiser said it would discontinue “clinically proven” claims and the claims “stops dry mouth” and “reverses dry mouth,” and modify claims other claims to more clearly focus on symptom relief.  NAD noted in its decision that the discontinued claims will be treated for compliance purposes as though NAD recommended their discontinuance or modification and the advertiser agreed to comply.

Turning its attention to the remaining and modified dry mouth-related claims, NAD reviewed the following claims made by the advertiser on its Oral Rinse packaging:

  • “Helps to sooth and moisturize a dry mouth”
  • “natural salivary enhancer”
  • “[created to] help patients with discomfort associated with dry mouth”
  • “Specially formulated with soothing natural enzymes and a gentle, plant-derived mouth-watering natural salivary enhancer that tingles and quickly moisturizes the mouth that releases saliva in the mouth”
  • “This professional formula helps quickly moisturize the mouth with soothing natural enzymes and a gentle plant-derived mouth-watering natural salivary enhancer that releases saliva into the mouth”
  • “Dentist Developed [or Dentist Formulated]”
  • “Satisfaction Guaranteed or Your Money Back.”

NAD also considered the following claims, made on packaging for the advertiser’s lozenges:

  • “Helps relieve dry mouth symptoms”
  • “natural salivary enhancer
  • ” “Helps revive natural mouth moisture”
  • “Contains a gentle plant-derived mouth-watering natural salivary enhancer that tinges and moisturizes the mouth”
  • “Dentist Developed [or Dentist Formulated]”
  • “Satisfaction Guaranteed or Your Money Back.”

The advertiser in this case relied primarily on consumer-use surveys and studies on certain ingredients as support for its health-performance claims. NAD took issue with certain features of the consumer-use surveys, including a failure to properly determine whether survey respondents displayed symptoms of dry mouth. NAD determined the advertiser did not submit sufficient evidence that the products at issue in the ingredient studies it provided had active ingredients in the same dosage and formulation as TheraBreath products.

Following its review, NAD determined that the evidence in the record was sufficient to support the advertiser’s “Dentist Developed [or Formulated]” and “Satisfaction Guaranteed or Your Money Back” claims.

NAD recommended the advertiser discontinue the remaining challenged health-performance claims.

In its advertiser’s statement, the company noted that its “strongly disagrees with the NAD’s adverse findings and conclusions … with regard to the symptoms relief claims made for the TheraBreath Dry Mouth Oral Rinse and Lozenges. Katz believes the substantiation analysis in the decision rests on a faulty legal premise and is conceptually incorrect, particularly its finding that the appropriate level of evidence required to substantiate health claims ‘generally means randomized, placebo-controlled studies on human beings that reach statistical significance and also yield clinically meaningful results.’”

While Katz “certainly respects the NAD’s authority and views, it intends to appeal the decision,” the company said.

Note: A recommendation by NAD to modify or discontinue a claim is not a finding of wrongdoing and an advertiser’s voluntary discontinuance or modification of claims should not be construed as an admission of impropriety. It is the policy of NAD not to endorse any company, product, or service. Decisions finding that advertising claims have been substantiated should not be construed as endorsements.

 

Subscribe to the Ad Law Insights or Privacy Initiatives newsletters for an exclusive monthly analysis and insider perspectives on the latest trends and case decisions in advertising law and data privacy.

 

 

 

 

Latest Decisions

Decision

National Advertising Division Recommends Blueprint Test Preparation Discontinue Certain MCAT Score Improvement Claims

New York, NY – April 22, 2024 – The National Advertising Division recommended Blueprint Test Preparation discontinue certain express and implied claims made in connection with its four MCAT preparation courses, including claims that Blueprint students raise their MCAT scores by 15 or 13 points on average.

Read the Decision Summary
Decision

National Advertising Division Recommends The Princeton Review Discontinue Point Increase Claims for MCAT Test Preparation Services

New York, NY – April 18, 2024 – In a Fast-Track SWIFT challenge, the National Advertising Division recommended that The Princeton Review (TPR) discontinue claims that its students “Score a 515+ on the MCAT or add 15 points depending on your starting score. Guaranteed or your money back.”

Read the Decision Summary
Decision

Direct Selling Self-Regulatory Council Recommends Trades of Hope Discontinue Salesforce Member Earnings Claims

McLean, VA – April 17, 2024 – The Direct Selling Self-Regulatory Council (DSSRC) recommended that Trades of Hope discontinue certain earnings claims made by salesforce members on Facebook and YouTube. 

Read the Decision Summary
Decision

National Advertising Division Recommends Lily of the Desert Nutraceuticals Discontinue “100% Pure Avocado Oil” Claim for Tropical Plantation Avocado Oil

New York, NY – April 15, 2024 – The National Advertising Division recommended that Lily of the Desert Nutraceuticals discontinue the claim “100% Pure Avocado Oil” for its Tropical Plantation Avocado Oil and avoid conveying the unsupported message that the product is 100% pure avocado...

Read the Decision Summary